Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Author: AbeM, BakerD R, HaemmerleS, KonnoP, LangleyR G, PapavassilisC, PappK A, RichardsH B, SigurgeirssonB, ThurstonH J

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Current treatments for psoriasis, including medications and biologics, have limitations in effectiveness or long-term safety. IL-17A, a molecule involved in inflammation, plays a key role in psoriasis. Targeting IL-17A with new therapies could offer a potential treatment approach.
Paper Details　
Original Abstract of the Article :
Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long-term safety. Interleukin (IL)-17A is believed to be an important effector cytokine in the pathogen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/bjd.12110

データ提供：米国国立医学図書館（NLM）

Secukinumab: A New Oasis in the Desert of Psoriasis Treatment

Psoriasis, an autoimmune condition that affects the skin, can feel like a relentless desert, with persistent itching, flaking, and discomfort. This study explores the potential of secukinumab, a new biologic medication that targets interleukin-17A, a key inflammatory protein implicated in psoriasis. The researchers aimed to evaluate the effectiveness and safety of secukinumab in treating moderate-to-severe plaque psoriasis, a common form of the disease.

Finding Relief in the Desert of Psoriasis

The results were encouraging, showing that secukinumab effectively reduced psoriasis symptoms and improved skin clearance. This finding suggests that secukinumab could provide a new oasis of relief for patients struggling with moderate-to-severe psoriasis. The study also found that secukinumab was generally well tolerated, a reassuring sign for patients who may be concerned about side effects.

Navigating the Desert with a New Compass

This research offers a new compass for navigating the desert of psoriasis treatment. While conventional therapies have limitations, secukinumab represents a promising new option that could provide significant relief for patients. This finding is particularly encouraging as it suggests that targeting specific inflammatory pathways may hold the key to more effective and targeted treatment strategies.

Dr. Camel's Conclusion

This study provides valuable insights into the potential of secukinumab as a treatment for psoriasis. By targeting interleukin-17A, this new medication offers a promising approach to reducing inflammation and improving skin clearance. As we continue to explore innovative treatment options, we are hopeful that we can find more effective and safe ways to help patients navigate the desert of psoriasis and find a more comfortable and fulfilling oasis.

Date :
  1. Date Completed 2013-07-18
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

23106107

DOI: Digital Object Identifier

10.1111/bjd.12110

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.